结肠癌根治术后辅助化疗的疗效及影响预后的多因素分析被引量：21

下载PDF

导出

摘要目的分析结肠癌根治术后辅助化疗对患者的疗效及影响其预后的多因素。方法回顾性分析接受结肠癌根治术的患者180例,其中接受术后辅助化疗者95例为观察组;未接受术后辅助化疗者85例为对照组。比较两组病理特征及疗效,并分析影响观察组预后的单因素及多因素情况。结果观察组临床分期为Ⅱ期占比明显低于对照组,Ⅲ期占比明显高于对照组(P<0.05)。观察组的复发率、转移率、1年生存率及2年生存率与对照组比较无显著差异(P>0.05)。观察组5年生存率明显高于对照组(P<0.05)。观察组生存时间<5年者的临床分期为Ⅲ期、CA19-9水平升高及分化程度为低分化的比例均明显高于生存时间≥5年者(P<0.05)。影响观察组预后的危险因素包括临床分期为Ⅲ期、CA19-9水平升高及分化程度为低分化。结论对结肠癌患者在实施根治性手术治疗后给予辅助化疗有利于提高远期疗效。

作者聂双发费建东李磊杜园杨本鑫郭迎雪

机构地区河北北方学院附属第一医院

出处《中国老年学杂志》 CAS 北大核心 2018年第2期352-354,共3页 Chinese Journal of Gerontology

关键词结肠癌根治术辅助化疗疗效预后多因素

分类号 R735.35 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1谢保红.不同辅助化疗方案治疗结肠癌的疗效对比分析[J].浙江临床医学,2016,18(3):522-523. 被引量：15
2肖毅,徐徕,陆君阳.根治性右半结肠癌淋巴结清扫范围的探讨[J].中华外科杂志,2016,54(6):408-412. 被引量：14
3伍海锐,王今,金岚,张忠涛.腹腔镜联合肛门内镜手术与传统腹腔镜辅助左半结肠癌根治术疗效对比[J].中华普通外科杂志,2016,31(5):421-422. 被引量：15
4黄勇平,刘忠民,高峰,钟毓杰,黄海球.结肠癌手术中完整结肠系膜切除的临床应用[J].中国现代普通外科进展,2016,19(3):205-208. 被引量：20
5卢杏生,徐勇,秦安成.完整结肠系膜切除治疗老年肥胖患者结肠癌的临床效果[J].中国医药,2016,11(5):691-693. 被引量：6
6宗殿亮.腹腔镜根治术与传统开腹手术治疗结肠癌效果及安全性对比研究[J].中国医学前沿杂志（电子版）,2016,8(4):73-75. 被引量：13
7秦琼,杨林,孙永琨,应建明,宋岩,张雯,王金万,周爱萍.老年结肠癌患者根治术后辅助化疗疗效及影响预后的多因素分析[J].中华老年医学杂志,2016,35(3):296-300. 被引量：39

二级参考文献87

1谢勤丽,王灿.老年人结肠癌手术治疗中完整结肠系膜切除术的安全性及可行性[J].中国老年学杂志,2015,35(2):399-400. 被引量：53
2Chen W. Report of incidence and mortality in China cancer registries, 2012. Chinese Journal of Cancer Research, 2013, 25(1): 10-19.
3Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy incolon cancer: observations based on individual, patient data from 20, 898 patients on 18 randomized trials. J ClinOncol, 2009, 27(6): 872-877.
4Sargent DJ, Marsoni S, Monges G, et al. Defective mismatchrepair as a predictive marker for lack of efficacy of fluorouracil based adjuvant therapy in colon cancer. J ClinOncol, 2010,28(30): 4664.
5Schmoll HJ, Cartwright T, TabemeroJ, eval. Phase trial ofcapecitabine plus oxaliplatin as adjuvant ther0y for stage III colon cancer: a planned safety analysis in 1,864 patients. JClinOncol, 2007, 25(1): 102-109.
6Siegel R.Cancer statistics,2014. CA: a catcer journal for clinicians, 2014, 64(1): 9-29.
7Andre T, Boni C, Navarro M, et al. A: InSproved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trial. J Clio, Orl12009, 27(19): 3109-3116.
8Sargent DJ, Patiyil S, Yothers G, et al: End points for colon/zancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the accent group. J Cfin0ncol, 2607,25(29): 4569-4574.
9Andre T. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 orModified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current colorectal cancerreports, 2013, 9(3): 261-269.
10Muss HB, Bynum DL. Adjuvant chemotherapy in older patients with stage Ill colon cancer: an underused lifesaving treatment [J]. J Clin Oncol, 2012, 30 ( 21 ): 2576-2578. IX)h 10. 1200/ JCO. 2012.42. 3780.